Matuzumab

马妥珠单抗

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMatuzumab
Drug Alias Name玛妥珠单抗MatuzumabumAnti-EGFR monoclonal antibody (Lilly)EMD-72000
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustriaGermany +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmd Serono IncTakeda Pharmaceutical Co LtdMerck KGaA, Darmstadt, Germany
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsOvarian Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank